Quick Answer
Tvardi Therapeutics, Inc. reported Cash and Equivalents of $20.73 million for fiscal year 2025.
Tvardi Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.73M | -34.4% |
| 2024 | $31.61M | -38.9% |
| 2023 | $51.77M | -18.8% |
| 2022 | $63.74M | +373.8% |
| 2021 | $13.45M | -57.5% |
| 2020 | $31.68M | +73.1% |
| 2019 | $18.30M | +21.4% |
| 2018 | $15.08M | +60.6% |
| 2017 | $9.39M | -22.4% |
| 2016 | $12.09M | -19.9% |
| 2015 | $15.10M | -71.3% |
| 2014 | $52.66M | +326.2% |
| 2013 | $12.36M | +1006.3% |
| 2012 | $1.12M | -72.7% |
| 2011 | $4.10M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.42M | -42.2% | +3.7% |
| June 30, 2025 | $20.65M | -58.1% | -39.7% |
| March 31, 2025 | $34.22M | -27.2% | +8.2% |
| December 31, 2024 | $31.61M | -38.9% | -14.7% |
| September 30, 2024 | $37.06M | -41.1% | -24.7% |
| June 30, 2024 | $49.24M | -15.5% | +4.8% |
| March 31, 2024 | $47.00M | -0.8% | -9.2% |
| December 31, 2023 | $51.77M | -18.8% | -17.7% |
- Tvardi Therapeutics, Inc. showed a decrease of -34.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Tvardi Therapeutics, Inc.’s cash and equivalents has grown by 406.1% (from $4.10 million to $20.73 million).
- The most recent figure is from Tvardi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: